Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyPrime Therapeutics Corlanor Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    HCN Channel Blocker Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and quantity-limit requirements for Corlanor (ivabradine) oral solution and tablets for Boeing commercial members, including initial and renewal criteria, heart-failure requirements, prescriber qualifications, safety screening, and dose limits.

    Policy Summary
    PayerPrime Therapeutics
    PolicyHCN Channel Blocker Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable indication, clinical criteria, specialist involvement, and absence of contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    600 mL/30 daysOral solution limit
    60 tablets/30 daysTablet limit
    ≤35%LVEF threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥70 bpmResting heart rate

    Coverage Criteria

    Initial evaluation

    Initial therapy is covered when all applicable requirements are met.

    Initial approval

    • Eligibility pathway

      • Continuation pathway: The requested agent is eligible for continuation; the patient has been treated with the requested agent within the past 90 days; treatment did not begin only with samples; and the patient is at risk if therapy is changed.Within the past 90 days
      • Clinical indication pathway

        • Dilated cardiomyopathy heart-failure pathway: The patient has stable symptomatic heart failure, NYHA Class II-IV, due to dilated cardiomyopathy; is in sinus rhythm; and has an elevated heart rate.NYHA Class II-IV
        • Chronic heart-failure pathway

          • Background therapy: For each applicable class, the patient is taking and will continue maximally tolerated beta-blocker, MRA, SGLT inhibitor, and ACEi/ARB/ARNI therapy in combination with the requested agent, or has intolerance, hypersensitivity, or an FDA-labeled contraindication to all agents in that class.
        • Other FDA-labeled or compendia-supported indication: The requested agent and route of administration have another FDA-labeled indication, and the patient's age is within FDA labeling, supported for the patient's age, or the indication is supported in compendia.AHFS or DrugDex level 1, 2a, or 2b evidence when compendia support is used
    • Provider and safety requirements: The prescriber is a specialist in the area of the patient's diagnosis or has consulted with an appropriate specialist, and the patient does not have any FDA-labeled contraindication to the requested agent.

    Renewal evaluation

    Renewal is covered when all renewal requirements are met.

    Renewal approval

    • Chronic heart-failure maintenance criteria when applicable

      • Background therapy: For each applicable class, the patient is taking and will continue the maximally tolerated therapy in combination with the requested agent, or has intolerance, hypersensitivity, or an FDA-labeled contraindication to all agents in that class.
    • Provider and safety requirements: The prescriber is a specialist in the area of the patient's diagnosis or has consulted with an appropriate specialist, and the patient does not have any FDA-labeled contraindication to the requested agent.

      Renewal approval is for 12 months.

    Quantity-limit criteria

    Quantity-limit approval is covered when one of the following is met.

    Quantity-limit approval

    • Within program limit: The requested quantity or dose does not exceed the program quantity limit.
    • Exceeds program limit

      • No maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the indication, and the requested quantity or dose is supported for the indication.
      • Higher strength and lower quantity: The requested quantity can be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.
      • Dose above FDA-labeled maximum:

    Treatment initiated only with samples is not approvable for the continuation pathway. Continuation requires treatment with the requested agent within the past 90 days and documentation that the patient is at risk if therapy is changed.

    Clinical Thresholds and Quantity Limits

    Left ventricular ejection fraction
    MeasureLeft ventricular ejection fraction (LVEF)
    Threshold≤35%
    Applies toStable symptomatic chronic heart failure pathway
    Resting heart rate
    MeasureResting heart rate
    Threshold≥70 beats per minute
    Applies toStable symptomatic chronic heart failure pathway

    Prior Authorization and Documentation

    Note

    Target Agent and Available Strengths

    Corlanor (ivabradine) is the target agent. Requests may be submitted for oral solution 5 mg/5 mL or tablets in 5 mg and 7.5 mg strengths.

    • Generic agents: ivabradine HCl oral solution and ivabradine HCl tablets
    • Client formulary identified in the source: Boeing
    Prior Authorization

    Initial Authorization

    Initial authorization requires an eligible continuation-of-therapy request or an FDA-labeled or compendia-supported indication for the requested agent and route of administration. FDA-labeled indications must meet applicable age-support requirements, and the prescriber must document specialist involvement and absence of FDA-labeled contraindications.

    • Continuation: the patient has been treated with the requested agent within the past 90 days; treatment started with samples does not qualify; and the patient is at risk if therapy is changed.
    • Eligible new therapy may include stable symptomatic heart failure, NYHA Class II-IV, due to dilated cardiomyopathy (DCM), with sinus rhythm and elevated heart rate.

    Policy Background

    This policy addresses ivabradine therapy for selected patients with stable symptomatic heart failure, including NYHA class II-IV disease. Coverage pathways include heart failure due to dilated cardiomyopathy with sinus rhythm and an elevated heart rate, or chronic heart failure with LVEF ≤35%, sinus rhythm, and resting heart rate ≥70 beats per minute. Applicable cases also require maximally tolerated guideline-directed background therapy, or documented intolerance, hypersensitivity, or FDA-labeled contraindication to the relevant therapy class.

    Clinical Definitions

    NYHA Class II-IV
    AbbreviationNYHA Class II-IV
    Full termNew York Heart Association functional class II-IV
    Policy descriptionStable symptomatic heart failure
    DCM
    AbbreviationDCM
    Full termDilated cardiomyopathy
    Policy contextA qualifying cause of stable symptomatic heart failure
    Policy Summary
    PayerPrime Therapeutics
    PolicyHCN Channel Blocker Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing the applicable indication, clinical criteria, specialist involvement, and absence of contraindications.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Quantity LimitsPrior Authorization and DocumentationPolicy BackgroundClinical Definitions
    The requested quantity or dose exceeds the maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose for the requested indication.
    Continuation treatment history
    TreatmentRequested agent
    Required historyPatient has been treated with the requested agent within the past 90 days
    Continuation exceptionTreatment initiated only with samples is not approvable
    Oral solution quantity limit
    Dosage formIvabradine HCl oral solution 5 mg/5 mL
    Quantity limit600 mL per 30 days
    Day supply30 days
    Tablet quantity limit
    Dosage formIvabradine tablets
    Available strengths5 mg and 7.5 mg
    Quantity limit60 tablets per 30 days
  1. Eligible new therapy may include stable symptomatic chronic heart failure, NYHA Class II-IV, with LVEF ≤35%, sinus rhythm, and resting heart rate ≥70 beats per minute, subject to the required foundational therapies or documented exceptions.
  2. Another FDA-labeled indication or a compendia-supported indication may qualify when the indication and route are supported. Compendia allowed: AHFS or DrugDex evidence level 1, 2a, or 2b.
  3. Initial approval length: 12 months. If a quantity limit applies, separate quantity-limit criteria must also be met.
  4. Prior Authorization

    Renewal Authorization

    Renewal requires prior approval of the requested agent through the plan’s prior authorization process and documented clinical benefit. Patients without prior approval require initial evaluation review, and applicable chronic-heart-failure, concomitant-therapy, specialist, and safety requirements must continue to be met.

    • Document that the patient was previously approved through prior authorization and has had clinical benefit with the requested agent.
    • For stable symptomatic chronic heart failure, NYHA Class II-IV, not due to DCM, document the required beta blocker, MRA, SGLT inhibitor, and ACE inhibitor, ARB, or ARNi therapy, or the applicable intolerance, hypersensitivity, or FDA-labeled contraindication to each class.
    • Renewal approval length: 12 months. If a quantity limit applies, separate quantity-limit criteria must also be met.
    Billing Rule

    Quantity-Limit Review

    Requests subject to a quantity limit must satisfy the separate quantity-limit clinical criteria in addition to the applicable prior authorization criteria.

    • The requested dose or quantity does not exceed the program quantity limit; or
    • The requested dose or quantity exceeds the program limit and the request includes a qualifying clinical rationale under the quantity-limit criteria.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Denial Risk

    Clinical Criteria Not Met

    Authorization is at risk for denial when the request does not establish eligible continuation therapy or an FDA-labeled or compendia-supported indication for the requested agent and route of administration.

    • FDA-labeled indications must meet the applicable age requirement or have support for use at the patient’s age.
    • Compendia support must be for the requested agent and route of administration and meet AHFS or DrugDex evidence level 1, 2a, or 2b.
    • Required diagnosis, NYHA class, rhythm, heart-rate, LVEF, treatment-history, specialist, or clinical-benefit documentation must be supplied when applicable.
    Denial Risk

    Contraindication or Foundational-Therapy Issue

    Denial risk applies when the patient has an FDA-labeled contraindication to the requested agent or when required foundational therapy criteria are not met and no qualifying exception is documented.

    • Document intolerance, hypersensitivity, or FDA-labeled contraindication to all agents in a required foundational-therapy class when combination therapy cannot be used.
    • For applicable chronic heart failure, failure to address beta blocker, MRA, SGLT inhibitor, or ACEi/ARB/ARNi requirements may result in denial.
    • The prescriber must attest that the patient does not have an FDA-labeled contraindication to ivabradine.
    Denial Risk

    Unsupported Quantity-Limit Override

    A quantity-limit override requires a qualifying dose or quantity rationale when the requested quantity exceeds the program limit. The submission should explain why the requested dose cannot be supplied within the limit using the available strength and why the higher dose is clinically supported.

    • Document that the requested quantity exceeds the program limit and provide the requested dose.
    • Where applicable, document that the requested agent does not have a maximum FDA-labeled dose for the indication and that the dose cannot be achieved with a lower quantity of a higher strength without exceeding the program limit.
    • If the requested quantity exceeds the maximum FDA-labeled dose for the indication, provide support for therapy at the higher dose.
    • Quantity-limit approval length: 12 months.
    ACEi/ARB/ARNI
    AbbreviationACEi/ARB/ARNI
    Expanded termsAngiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or angiotensin receptor-neprilysin inhibitor
    Therapy requirementThe applicable therapy is continued in combination with the requested agent, unless a qualifying class intolerance, hypersensitivity, or contraindication applies
    MRA
    AbbreviationMRA
    Full termMineralocorticoid receptor antagonist
    Policy examplesEplerenone, finerenone, or spironolactone
    SGLT inhibitor
    AbbreviationSGLT inhibitor
    Full termSodium-glucose cotransporter 2 inhibitor
    ExamplesDapagliflozin, empagliflozin, or sotagliflozin